Seed develops synbiotics for stimulating the gut microbiome, using metabolomic sequencing and a proprietary screening platform for host mechanistic pathways. The company's probiotics contain GRAS and QPS status strains that have shown improvements in gastrointestinal, cardiovascular, and dermatological health markers. Founded in 2016 in Los Angeles, United States, the company has raised $40.6M in Series A funding from investors including The Craftory, Artis Ventures, and Founders Fund. Developer synbiotics for simulating the gut microbiome. The company metabolomic sequencing and has developed a proprietary screening platform for the screening of host mechanistic pathways. The company claims that the probiotics developed to contain the strains having GRAS and/or QPS (Qualified Presumption of Safety) status.
Seed
Series ASeed develops synbiotics for stimulating the gut microbiome, using metabolomic sequencing and a proprietary screening platform for host mechanistic pathways. The company's probiotics contain GRAS and QPS status strains that have shown improvements in gastrointestinal, cardiovascular, and dermatological health markers. Founded in 2016 in Los Angeles, United States, the company has raised $40.6M in Series A funding…
About
Business model
Genomics > Applied Genomics > Consumer Genomics > Microbiomics,
Nutraceuticals Tech > Functional Foods and Beverages > Probiotics > Oral Health
Founders & team highlights
Founder with Prior Funding,
Serial Founder
Institutional investors
Latest coverage
📰 Latest funding news — recent raises and deal signals across the ecosystem.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.